Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 9/20 | 0.39 |
| ▸ | AR | P10275 | 7/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14805105 | 0.83 | PGR (0.44) | PGRARNR3C1NR3C2KDM4E | |
| SCHEMBL2590266 | 0.79 | AR (0.45) | PGRARNR3C1NR3C2 | |
| SCHEMBL14819171 | 0.78 | IMPDH2 (0.43) | PGRNR3C1NR3C2KDM4ETDP1 | |
| SCHEMBL14727014 | 0.75 | P2RX3 (0.32) | — | |
| SCHEMBL14727054 | 0.70 | EZH2 (0.40) | KDM4EALDH1A1 | |
| SCHEMBL18585239 | 0.70 | MEN1 (0.38) | PGRARNR3C1NR3C2 | |
| SCHEMBL1484637 | 0.69 | KDM5A (0.34) | PGRNR3C1NR3C2 | |
| SCHEMBL10095261 | 0.67 | XDH (0.43) | PGRARNR3C1NR3C2KDM4E | |
| SCHEMBL28592975 | 0.67 | XDH (0.45) | PGRARNR3C1NR3C2KDM4E | |
| SCHEMBL9043552 | 0.66 | MAOA (0.41) | ARKDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9649307-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160296518-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| US-9446041-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9402836-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160074394-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2016-03-17 | — | — | US | disclosed |
| US-9242962-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20150313887-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2015-11-05 | — | — | US | disclosed |
| US-9114141-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150141436-A1 | INDOLES | KIDS2, INC. | 2015-05-21 | — | — | US | disclosed |
| US-8975291-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140256739-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2014-09-11 | — | — | US | disclosed |
| US-8536179-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2013-09-17 | — | — | US | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-8334295-B2 | Pyrimidine derivatives as HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-12-18 | — | — | US | disclosed |
| US-20110076276-A1 | Novel HIV reverse transcriptase inhibitors | GILEAD SCIENCES, INC. (US) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160074394-A1 | METHOD OF TREATMENT | EZH1, EZH2, SUV39H2 | PGR 4210/4885AR 2139/4885NR3C1 122/4885 |
| US-20110076276-A1 | Novel HIV reverse transcriptase inhibitors | POLR2E, POLR1E, POLR2H | PGR 1957/4885AR 2175/4885NR3C1 1133/4885 |
| US-20150141436-A1 | INDOLES | IDO1, IDO2, INMT | PGR 391/4885AR 262/4885NR3C1 1377/4885 |
| US-20140256739-A1 | METHOD OF TREATMENT | EZH1, EZH2, SUV39H2 | PGR 4210/4885AR 2139/4885NR3C1 122/4885 |
| US-20150313887-A1 | INDOLES | IDO1, IDO2, INMT | PGR 391/4885AR 262/4885NR3C1 1377/4885 |
| US-20130053397-A1 | INDOLES | IDO1, IDO2, INMT | PGR 373/4885AR 241/4885NR3C1 1408/4885 |
| US-20160296518-A1 | INDOLES | IDO1, IDO2, INMT | PGR 391/4885AR 262/4885NR3C1 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.